...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New shares issued?

Quest13,

Zenith Epigenetics Ltd (ZEL) is a wholly-owned subsidiary of Zenith Capital Corp (ZCC). Although the whole Zenith enchilada (ZEL + ZCC) may be sold together, it is also possible that just ZEL could be sold off. Under that scenario, current ZCC shareholders would still retain their ZCC shares and ZCC would still retain rights to the Resverlogix royalty preferred shares. Other spin-off scenarios are also possible too that would still allow royalty income to flow into ZCC.

BearDownAZ

Share
New Message
Please login to post a reply